{"title": "A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity", "author": "Fraiser Kansteiner", "url": "https://www.fiercepharma.com/pharma/once-and-future-glp-1-king-novo-nordisk-ceo-talks-wegovy-manufacturing-and-alzheimers", "hostname": "fiercepharma.com", "description": "Novo Nordisk's recent growth renaissance has arrived thanks in no small part to semaglutide\u2014the GLP-1 molecule behind the company's leading marketed trio of Ozempic, Rybelsus and Wegovy. | Novo Nordisk's recent growth renaissance has flourished thanks in no small part to semaglutide\u2014the GLP-1 molecule behind the company's leading trio of Ozempic, Rybelsus and Wegovy. But even as the drug's metabolic empire prospers, Novo Nordisk isn't letting its GLP-1 rest on its laurels.", "sitename": "FiercePharma", "date": "2022-08-29", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}